gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

V-erb-b2 erythroblastic leukemia viral oncogene homolog 3

erbB-3, HER3
This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008] (from NCBI)
Sponsored links
Top mentioned proteins: erbB-2, EGFR, ErbB4, Akt, CAN
Papers using erbB-3 antibodies
Regulation of the PMP22 Gene through an Intronic Enhancer
McCallion Andrew S et al., In BMC Developmental Biology, 2010
... ERBB3_MCS6 transgenic fish upon sox10 morpholino ...
Breaking down the barriers: siRNA delivery and endosome escape
Giangrande Paloma H. et al., In Nucleic Acids Research, 2009
... Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human ...
Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Verma Chandra, In PLoS ONE, 2008
... The affinity maturated, HER3-specific Affibody molecules His-Z05416-Cys and His-Z05417-Cys ...
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
Stern D F et al., In British Journal of Cancer, 2007
... Rabbit anti-EGFR, mouse anti-EGFR, rabbit anti-Met, rabbit anti-Her2, mouse anti-Her3, mouse IgG, goat antimouse HRP and goat antirabbit HRP antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); ...
Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model
Segall Jeffrey E. et al., In Oncogene, 2005
... Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human ...
more suppliers
Papers on erbB-3
HER3/ErbB3, an emerging cancer therapeutic target.
An et al., Houston, United States. In Acta Biochim Biophys Sin (shanghai), Jan 2016
HER3 is a member of the HER (EGFR/ErbB) receptor family consisting of four closely related type 1 transmembrane receptors (EGFR, HER2, HER3, and HER4).
Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases.
Kiura et al., Okayama, Japan. In Cancer Res, Jan 2016
One cell line lost the EML4-ALK fusion gene, but exhibited increased activation of insulin-like growth factor-1 receptor (IGF-1R) and human epidermal growth factor receptor 3 (HER3), and overexpressed the HER3 ligand neuregulin 1. Accordingly, pharmacologic inhibition of IGF-1R and HER3 signaling overcame resistance to alectinib in this cell line.
Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Tiwari et al., Valhalla, United States. In Oncotarget, Jan 2016
Expression of membrane receptors HER2 and HER3 was greatly amplified in the resistant cancer cells.
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.
Deeni et al., Edinburgh, United Kingdom. In Oxid Med Cell Longev, Dec 2015
Here, we have demonstrated that pharmacological activation of NRF2 by tert-butylhydroquinone (tBHQ) upregulates the HER family receptors, HER2 and HER3 expression, elevates pAKT levels, and enhances the proliferation of ovarian cancer cells.
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Daub et al., Martinsried, Germany. In Plos One, Dec 2015
The four members of the epidermal growth factor receptor (EGFR/ERBB) family form homo- and heterodimers which mediate ligand-specific regulation of many key cellular processes in normal and cancer tissues.
Immunohistochemical Assessment of HER3 Expression in Odontogenic Cysts.
Torabi Parizi et al., Zāhedān, Iran. In Iran Red Crescent Med J, Nov 2015
BACKGROUND: It has been demonstrated that HER3 plays an important role in some human cancers and the HER3 expression is associated with worse survival in solid tumors.
Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Calleja-Hernández et al., Granada, Spain. In Breast Cancer Res Treat, Oct 2015
Some molecular mechanisms have been proposed to be responsible for this resistance, such as activation of alternative signaling pathways (through ERBB receptors and non-ERBB receptors or increased expression of ligands and alterations in HER2 signaling components).
Genomic classification of lung cancer: toward a personalized treatment.
El Mezni et al., In Tunis Med, Jun 2015
Upon binding to its ligands, EGFRforms homodimers or heterodimers with other family members(ERBB2, ERBB3 or ERBB4),which inactivate intrinsic receptor tyrosine kinase activity and trigger a phosphorylation cascade of specific tyrosine residues within their cytoplasmicregulatory domains(3).
The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis.
Lin et al., Ann Arbor, United States. In Nat Med, 2014
Mechanistically, Nrg4 activates ErbB3 and ErbB4 signaling in hepatocytes and negatively regulates de novo lipogenesis mediated by LXR and SREBP1c in a cell-autonomous manner.
Role of ErbB Receptors in Cancer Cell Migration and Invasion.
Bennasroune et al., Reims, France. In Front Pharmacol, 2014
The ErbB receptor family of RTKs comprises four distinct receptors: the EGFR (also known as ErbB1/HER1), ErbB2 (neu, HER2), ErbB3 (HER3) and ErbB4 (HER4).
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
Győrffy et al., Budapest, Hungary. In Curr Cancer Drug Targets, 2014
These include HER2 amplification, impaired access to the binding site (p95HER2, Δ16HER-2, MUC4), augmented signaling through other ERBB family receptors (HER1, HER3, HER4) and their ligands, activation of HER2 targets by alternate heterodimers (EphA2, IGF-1R, GDF15, MUC1*), signaling triggered by downstream members (PIK3CA, PTEN, SRC, mTOR), altered expression of cell cycle and apoptotic regulators (CDKs, p27(kip1), Bcl-2), hormone receptor status, resistance to antibody-dependent cellular cytotoxicity (FcγR), and altered miRNA expression signatures.
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Swain et al., Barcelona, Spain. In J Clin Oncol, 2014
PATIENTS AND METHODS: Mandatory tumor and serum samples were collected (N = 808; 58% to 99.8% were assessable), and amphiregulin, betacellulin, epidermal growth factor (EGF), transforming growth factor alpha, EGF receptor, HER2, HER3, insulin-like growth factor 1 receptor, PTEN, phosphorylated AKT, PIK3CA, CMYC, serum HER2 extracellular domain (sHER2), and FCγR were assessed using appropriate assays.
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.
Liu et al., Shanghai, China. In Nat Genet, 2014
Moreover, ErbB signaling (including EGFR, ERBB2, ERBB3, ERBB4 and their downstream genes) is the most extensively mutated pathway, affecting 36.8% (21/57) of the GBC samples.
Hematogenous metastasis of ovarian cancer: rethinking mode of spread.
Sood et al., Houston, United States. In Cancer Cell, 2014
Our studies revealed that the ErbB3-neuregulin 1 (NRG1) axis is a dominant pathway responsible for hematogenous omental metastasis.
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Moasser et al., San Francisco, United States. In J Clin Oncol, 2014
PURPOSE: The highly effective treatment of human epidermal growth factor receptor (HER) 2-amplified breast cancer has proven challenging because of a signal buffering capacity inherent in the functionally relevant HER2-HER3 target.
Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
Landgraf et al., Miami, United States. In Proc Natl Acad Sci U S A, 2012
Higher order complexes of nonoverexpressed ERBB receptors are an integral and qualitatively distinct part of normal ERBB2/ERBB3 signaling.
Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3.
Hu et al., Chongqing, China. In J Cancer Res Clin Oncol, 2012
Data show that miR-22 inhibited the expression of ErbB3 through post-transcriptional regulation via binding to ErbB3 3' untranslated regions (3'-UTR).
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.
Engelman et al., Boston, United States. In Cancer Res, 2012
Mutation of this amino acid led to increased ERBB receptor activation and upregulation of the ERBB3/PI3K/AKT signaling pathway, which was no longer responsive to MEK inhibition
Expression of activated type I receptor tyrosine kinases in early breast cancer.
Bartlett et al., Toronto, Canada. In Breast Cancer Res Treat, 2012
HER3 expression was significantly associated with patients who have post-menopausal high tumour grade progesterone receptor negativity.
Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Muller et al., Montréal, Canada. In Cancer Res, 2012
findings indicate that although ErbB3-associated PI3K activity is critical for mammary development, it is dispensable for ErbB2-induced mammary tumor progression
More papers using erbB-3 antibodies
Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer
Adams G P et al., In British Journal of Cancer, 2005
... Expression levels of ErbB2 and ErbB3 on each of the cell lines used in this study were measured by quantitative flow cytometry with the QuantiBrite System (Becton Dickinson) using the manufacturer's protocols ...
The transcription factors SCIP and Krox-20 mark distinct stages and cell fates in Schwann cell differentiation
Salzer James L. et al., In The Journal of Cell Biology, 1995
... Sinai Medical Center, New York, NY), antilaminin L-9393 (Sigma-Aldrich), anti–erbB2 sc-284, anti–erbB3 sc-285 (Santa Cruz Biotechnology, Inc.), and anti–suppressed cAMP-inducible ...
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
POLK D. BRENT et al., In Laboratory Investigation; a Journal of Technical Methods and Pathology, 1995
... Experiments began four weeks following tamoxifen to allow for efficient Cre-mediated recombination of the floxed ErbB3 allele.To induce colitis, mice received DSS (36–50 kDa; MP Biomedicals, Solon, OH) dissolved in ...
The antiviral, antitumoral xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C
Podo Franca et al., In Breast Cancer Research : BCR, 1995
... Rabbit anti-EGFR, anti-HER2, anti-HER3, and anti-Rab5B pAbs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Faivre-sarrailh Catherine, In PLoS ONE, 1975
... Anti-erbB3 (C-17; sc-285) polyclonal antibody was from Santa Cruz Biotechnology.
share on facebooktweetadd +1mail to friends